 BOSTON--BUSINESS WIRE--- KRTX NEJM--Karuna Therapeutics, Inc. NASDAQ: KRTX, a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that results from the EMERGENT-1 Phase 2 clinical trial evaluating KarXT for the treatment of schizophrenia were published in the New England Journal of Medicine NEJM. The publication of the EMERGENT-1 Phase 2 trial results in the peer-reviewed New Eng 